Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound. The pharma company ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy will have the option to buy now and pay later under a partnership announced Tuesday by ...

Amgen’s most advanced obesity asset MariTide ... that the findings were “roughly on par” with Eli Lilly’s weekly Zepbound (tirzepatide), meaning that MariTide’s “only differentiation ...

Despite that assessment, shares in Amgen lost nearly 5% of their value ... better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) This could end up making your wallet lighter if you are taking Ozempic or Zepbound for diabetes or weight loss. From 2024 to ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Amgen’s stock has been rising consistently ... s LLY and Novo Nordisk’s NVO popular GLP-1-based obesity drugs, Zepbound and Wegovy, which are weekly injections.